| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H28N2O3 |
| Molecular Weight | 392.4907 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)C1=CC=C(C(O)=C1)C2=CC3(CCNCC3)OC4=C2C=CC=C4
InChI
InChIKey=ALGHKWSXJUQNJJ-UHFFFAOYSA-N
InChI=1S/C24H28N2O3/c1-3-26(4-2)23(28)17-9-10-18(21(27)15-17)20-16-24(11-13-25-14-12-24)29-22-8-6-5-7-19(20)22/h5-10,15-16,25,27H,3-4,11-14H2,1-2H3
| Molecular Formula | C24H28N2O3 |
| Molecular Weight | 392.4907 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Adolor Corporation and Pfizer were developing an orally available and selective opioid delta (δ) receptor agonist, ADL 5747 (also known as PF 04856881), for the treatment of pain. ADL-5747 showed efficient pain-reducing properties in the two preclinical models of chronic pain. Their effects were mediated by δ-opioid receptors, with a main contribution of receptors expressed on peripheral Nav1.8-positive neurons. ADL-5747 had been in phase II clinical trials for the treatment of pain. However, this studies on this drug candidate were discontinued in 2010.
